CymaBay Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan disorders. Arhalofenate, the Company’s lead product candidate, is used to treat gout. The Company has completed five Phase II clinical trials of Arhalofenate in patients with gout. The Company’s second product candidate, MBX-8025, is used to treat disorder linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. The Company has completed five Phase I and one Phase II clinical trials of MBX-8025. The Company’s MBX–2982 is a treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX–2982 has completed four Phase I studies and one Phase II study.
